Brief: Immuneering Announces Closing Of $25 Million Private Placement
Brief: Immuneering Reports Positive Overall Survival Data For Atebimetinib (Imm-1-104) From Phase 2A Trial In Pancreatic Cancer Patients
Brief: Immuneering Corporation Q4 Net Income USD 18.1 Million
U.S. STOCKS ON THE MOVE-Annovis Bio, Hoth Therapeutics, Digital Realty
U.S. STOCKS ON THE MOVE-Annovis Bio, Hoth Therapeutics, Digital Realty
U.S. STOCKS ON THE MOVE-Hims & Hers, UniFirst, Carvana
Immuneering soars on positive trial data for pancreatic cancer therapy
Brief: Immuneering Announces Positive Data Update From Three Pancreatic Cancer Arms Of Ongoing Phase 2A Trial Of IMM-1-104
U.S. STOCKS ON THE MOVE-Uber, silver miners, Arm
Immuneering jumps after positive initial data on cancer therapy
Brief: Immuneering Announces Positive Phase 2A Data With Imm-1-104 In Combination With Chemotherapy In Pancreatic Cancer
Immuneering shares rise as cancer therapy shows promising results in trial
Brief: Immuneering Announces First Patient Dosed In Its Phase 1/2A Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF, RAS Mutations
U.S. RESEARCH ROUNDUP-Evercommerce, Immuneering, Ulta Beauty
U.S. STOCKS ON THE MOVE-Robinhood Markets, ADM, Vaalco Energy
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Build-A-Bear, Spruce Biosciences
Immuneering rises after cancer drug shows promise in early-stage trial
Brief: Immuneering Announces Positive Topline Results From Phase 1 Portion Of Imm-1-104 In Ras-Mutant Solid Tumors
Brief: Immuneering Corporation Q4 net income USD -15.1 million